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ABSTRACT
Background: Mast cell tumors (MCT) are among the most common malignant cutaneous neoplasm in dogs with vari-
able biologic behavior and remain a therapeutic challenge in high-grade cases. Surgery remains the primary treatment for 
canine MCT; however, chemotherapy and radiation therapy are commonly used to treat aggressive cases. The combina-
tion of vinblastine (VBL) at a dose of 2 mg/m² and prednisone is the classically described protocol for MCT treatment. 
Studies have shown the safety of higher VBL doses for dogs with MCT, but there is a lack of information regarding dose 
intensity and outcome as a goal after chemotherapy. This study aimed to evaluate the impact of a higher dose of VBL on 
MCT treatment outcome. 
Materials, Methods & Results: This was an observational and comparative study conducted in two different Veterinary 
Teaching Hospitals. Client-owned dogs with histopathological diagnosis of grade II or III MCT were selected and under-
went at least four chemotherapy sessions with VBL and prednisone. The experimental group (EG) consisted of 18 dogs that 
received a dose of 3 mg/m² VBL treated in one institution. The control group (CG) included 31 dogs that received a dose 
of 2 mg/m² VBL treated at the other institution. All dogs treated in both groups had a clinical and complete blood count 
(CBC) evaluation performed previous the start of chemotherapy (T0) and before each weekly treatment (T1, T2, T3, and 
T4). After treatment, dogs in both groups were followed-up for the recurrence rate and overall survival time after diagno-
sis. There was no significant difference in clinical variables between EG and CG. During treatment, dogs of EG showed a 
significant reduction in erythrocyte, hemoglobin, and hematocrit values between T0 and T1, T2, T3, and T4 (P < 0.001). 
Comparatively, the CG showed significant reduction in hemoglobin (P = 0.02) and total leucocytes (P = 0.001) values in 
the same period. Despite these findings, these hematological parameters did not exceed the lower limit for the species in 
both groups. There was a higher-grade neutropenia one week after the first VBL application (T2) in both groups, with no 
statistical difference in neutrophil counts at T2 or during the whole treatment. There were discrete and self-limited episodes 
of anorexia, vomiting, and diarrhea in both groups. After chemotherapy, dogs in EG showed a significantly lower rate of 
recurrence than dogs in CG (P = 0.02). There was no significant difference in the overall survival time between groups. 
Discussion: The absence of significant differences in clinical variables (e.g. sex, age, histological grading, and tumor loca-
tion) between EG and CG suggests that the groups may be similar regarding these parameters. All dogs included in this 
study had a recommendation for MCT post-operative chemotherapy treatment. VBL action is non-selective and anemia is 
not a commonly described adverse effect associated with its administration. Despite that, EG dogs exhibited a reduction 
in erythrocytes, hematocrit, and hemoglobin, and CG dogs in hemoglobin throughout T0 to T4. The highest number of 
neutropenia episodes occurred during T2, after the first VBL application in both groups with a trend of stabilization after 
T2, which is compatible with findings described in the literature. Any dog of EG or CG had to interrupt the treatment due 
to hematological or gastrointestinal toxicity or died during treatment. The role of VBL dose intensity in outcome is still 
debatable for dogs with MCT, once it is a multifactorial disease with variable presentation. In this study, there was no 
difference in overall survival time after diagnosis between groups, and EG dogs treated with a higher VBL dose showed 
significantly less tumor recurrence than CG.
Keywords: chemotherapy, dog, mast cell tumor, vinblastine.
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INTRODUCTION
Mast cell tumor (MCT) represents one of the 
most common malignant tumors in dogs. It consists 
in a proliferation of neoplastic mast cells with vari-
able clinical presentation [6,17]. Histopathological 
examination is the main criteria for diagnosis [2]. 
Surgery remains the main choice for most cases of 
MCT. Chemotherapy and/or radiotherapy protocols 
are complementary treatments for high-grade tumors, 
incompletely excised MCTs, or disseminated/meta-
static cases [5,9,11]. Tumor recurrence and metastasis 
are common problems, especially in high-grade tumors 
[6,12,19]. 
Chemotherapy with VBL and prednisone has 
shown high efficacy in dogs with MCT, resulting in 
low recurrence rate and better overall survival time 
[9,20,24]. The most common protocol consists in VBL 
at 2 mg/m², by intravenous route, for four weekly ses-
sions, followed by four biweekly sessions. In addition, 
oral prednisone is combined at an initial dose of 2 mg/
kg, with decreasing doses over time [3,14]. 
Studies have demonstrated the safety of higher 
VBL doses [1,15,20,21]. Dogs treated with VBL at 3.5 
mg/m² showed better overall response rate than those 
treated with 2 mg/m², when the primary outcome was 
reduction in tumor size [20]. There are studies with 
escalating VBL doses for dogs, and the mean safe dos-
age ranged from 2.67 mg/m² to 3.5 mg/m² [1,21,23]. 
However, there is a lack of evidence that higher VBL 
doses may provide long-term therapeutic gains. This 
study aimed to evaluate adverse effects during treat-
ment, the recurrence rate and overall survival time after 
diagnosis in dogs with MCT treated with 3 mg/m² VBL 
(experimental group - EG), and compare to dogs from 
the control group (CG) treated with 2 mg/m2 VBL.
MATERIALS AND METHODS
Study subjects
This study was conducted in two different 
Veterinary Teaching Hospitals: The Veterinary Clinic 
School of the Pontifical Catholic University of Paraná 
(PUCPR), and at the Veterinary Hospital of the School 
of Agrarian and Veterinary Sciences, São Paulo State 
University (UNESP/FCAV), Jaboticabal, São Paulo, 
Brazil. This study involved an observational, compara-
tive, and quantitative approach. The EG was composed 
of 18 dogs prospectively followed at the PUCPR Vet-
erinary Clinic School. The CG was composed of 31 
dogs that underwent treatment at the UNESP/FCAV 
Veterinary Hospital. The PUCPR Ethics Committee 
for Animal Use approved this project under protocol 
01106/2016. All tutors of selected dogs signed a con-
sent form.
Patient Selection
The EG group consisted of client-owned dogs 
diagnosed with MCT. The inclusion criteria were as 
follows: dogs with histopathological diagnosis of MCT, 
complete treatment with at least four weekly applica-
tions of 3 mg/m² VBL (Faulblastina® Enj. Sol.)1 asso-
ciated to prednisone (Meticorten®)2, and dogs whose 
tutors agreed to participate in the study. Exclusion 
criteria were as follows: dogs diagnosed with MCT 
grade I/low grade; those with another type of tumor in 
addition to MCT; those with pre-existing chronic liver 
or kidney disease and/or cytopenias such as anemia, 
thrombocytopenia, and neutropenia. Thirty-two dogs 
with confirmed diagnosis of MCT were followed-up 
at the PUCPR Veterinary Clinic School. Of this total, 
five dogs did not undergo chemotherapy after surgery 
[due to death (n= 1) and refusal by the tutors (n= 4)], 
four dogs did not complete the minimum treatment, 
and five had grade I/low grade MCT diagnosis, which 
resulted in 18 dogs selected for EG. The inclusion and 
exclusion criteria were the same for CG, except that the 
dose of VBL used was 2 mg/m². Thus, CG comprised 
of 31 dogs treated at the UNESP/FCAV Veterinary 
Hospital during the study period. 
Diagnosis, staging, and surgical excision
The following information were collected 
for the EG and CG as medical history: age in years, 
sex, weight in kilograms, reproductive status (intact 
or neutered), history of previous surgical excision, 
disease onset time, number of lesions, tumor location, 
and presence of cutaneous ulcerations. Dogs in both 
groups underwent physical examination. The initial 
staging workup comprised of a test for complete blood 
count (CBC), serum biochemical analysis (alanine 
aminotransferase, alkaline phosphatase, urea, creatinine, 
total protein, albumin, and glucose), nodule cytology, 
and abdominal ultrasonography. All dogs in the EG 
underwent surgical excision (n= 18). In CG, 29 dogs 
underwent surgery for tumor removal, and two dogs had 
MCT classified as unresectable. After surgery, dogs were 
followed-up regularly during the postoperative period 
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to detect possible postoperative complications such as 
wound dehiscence, necrosis, ulceration, and local or 
distant recurrence. After surgery or biopsy, all tumors 
were evaluated by histopathological examination and 
classified using previously described grading systems 
[7,13]. In cases where the patient had multiple tumors 
with different grades, the highest grade was recorded.
Treatment and toxicity assessment
In both groups, chemotherapy consisted of at 
least four sessions each week, involving the intravenous 
administration of VBL. EG dogs received a VBL dose 
of 3 mg/m², while dogs in the CG received 2 mg/m² 
VBL per session. Dogs in both groups received oral 
prednisone at an initial dose of 2 mg/kg per day. There 
was a gradual weekly corticosteroid dose reduction to 
0.5 mg/kg per day, maintained until the end of treat-
ment. All dogs treated in both groups had a clinical and 
hematological evaluation by CBC performed before 
treatment (Time 0, T0). After the start of chemotherapy, 
all dogs had a CBC evaluation before each treatment, 
for a period of four weeks (T1, T2, T3, and T4). 
The occurrence of gastrointestinal adverse 
effects such as anorexia, vomiting, and diarrhea was 
recorded at each visit. Gastrointestinal toxicity was 
evaluated and graded from 0 to 5, as previously de-
scribed [22]. CBC data involving blood counts, leuko-
gram, and platelet values revealed possible hematologi-
cal toxicity. In both groups, treatment was postponed 
for at least seven days if there was pretreatment grade 
2 or higher neutropenia or gastrointestinal toxicity ≥ 
grade 2 dogs [22].  
Recurrence rate and survival time 
Dogs in the EG and CG were followed-up until 
the end of the study. The objective was to record local 
or distant recurrence, new localized or disseminated 
skin lesions, survival time, and occurrence of deaths. 
The team contacted the dog tutors by telephone for 
updates on patients that could not be followed-up; four 
dogs from the CG could not be followed-up until the 
end of the study. Information about recurrence after 
treatment and survival time was collected for 25 and 
27 of the 31 CG dogs, respectively. For EG dogs, data 
regarding recurrence after treatment and survival time 
was collected for all 18 cases. A comparison between 
the overall survival curves of the EG and CG dogs was 
performed, from the time between MCT diagnosis until 
the last follow-up or death. 
Statistical analysis
Absolute and relative frequencies and descriptive 
statistical measures were used for analyses of clinical and 
treatment variables. Descriptive statistics are reported as 
mean (standard deviation). Fisher’s exact test and Pear-
son’s Chi-square test were used to evaluate the association 
between categorical variables, and evaluation of adjusted 
residuals for variables with three or more categories. The 
Student’s t-test and Mann-Whitney test compared two in-
dependent groups. Comparisons over the treatment period 
(T0 to T4) were performed using the repeated measures 
analysis of variance (ANOVA) test, with Bonferroni cor-
rection, repeated measures Student’s t-test, and Friedman 
and Wilcoxon tests. Data gaussianity was verified using 
histograms and the Shapiro-Wilk test.
Multivariate ANOVA for repeated measures 
was used to compare hematological parameters dur-
ing treatment (T0 to T4) between groups (EG and 
CG). This test was applied only to variables that were 
significantly different in the bivariate analysis for both 
groups (hemoglobin and eosinophils). 
Comparison of the recurrence rate after treat-
ment between EG and CG was calculated using the 
Pearson Chi-square and then adjusted by logistic 
regression. Overall survival curves of follow-up after 
MCT diagnosis were compared between EG and CG 
dogs. Dogs with the last registered follow-up (cen-
sorship) and deaths (case) were considered. Survival 
functions were calculated using the Kaplan-Meier 
survival analysis with log-rank tests. The software used 
for statistical analysis was the Statistical Package for 
Social Science (SPSS), version 15.0 and the level of 
significance was set at P < 0.05 for all tests.
RESULTS
Among the 18 dogs in the EG, 10 (55.6%) were 
females and eight (44.4%) were males. Breeds included 
mixed (n= 7), Labrador retriever (n= 4), and one each of 
the following: Boxer, Brazilian Terrier, Pinscher, Pit Bull, 
Poodle, Rottweiler and Shar-Pei. Of the 31 CG dogs, 20 
(64.5%) were females and 11 (35.5%) were males. Breeds 
included mixed (n= 9), Boxer (n= 4), Dachshund (n= 4), 
Labrador Retriever (n= 3), Pit Bull (n= 3), Pinscher (n= 
2), Pug (n= 2) and one each of the following: Bernese 
Mountain Dog, Brazilian Terrier, Doberman, and Golden 
Retriever. The distribution of EG and CG according to 
clinical variables is presented in Table 1. The variables 
were not significantly different between groups.
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Table 2 shows the distribution of CBC parameters 
of EG at the beginning of treatment and during the sub-
sequent four sessions. There was a significant reduction 
in erythrocyte, hemoglobin, hematocrit, and eosinophil 
counts between T0 and T1, T2, T3, and T4 (P < 0.001). 
However, there was no significant difference between T0 
and T1 for erythrocytes, hemoglobin and eosinophils. In 
addition, there was no significant difference between T0 
and T3 for erythrocytes and hemoglobin. There was a sig-
nificant reduction in erythrocytes, hemoglobin, hematocrit 
and eosinophils between T0 and T2, and T0 and T4. The 
monocyte count increased significantly between T0 and 
T2 and between T0 and T3. Despite the variations in the 
aforementioned CBC parameters, the means were in the 
reference range for the species.
Table 3 shows the distribution of CBC parame-
ters of CG dogs during treatment. There was a significant 
difference in hemoglobin levels throughout the sessions, 
but no difference in specific comparison between T0 
and T1, T0 and T2, T0 and T3, and between T0 and T4. 
There was a significant reduction in total leukocyte and 
lymphocyte counts between T0 and T2 and between T0 
and T3. Eosinophil count showed significant reduction 
between T0 and T2, T3, and T4. Despite these variations, 
all the means and medians were within the reference 
range for dogs. There was no significant difference in 
neutrophils counts during the treatment for both groups.
When the EG and CG were compared using 
multivariate ANOVA for repeated measures, there 
was a significant reduction in hemoglobin (P < 0.001) 
and eosinophils (P < 0.001) in both groups during 
the four-week chemotherapy period. However, there 
was no significant difference in the values of these 
parameters between EG and CG when the VBL dose 
was considered as a dependent variable (P = 0.38 for 
hemoglobin and P = 0.86 for eosinophils).
Table 1. Distribution of Experimental and Control Groups according to clinical variables.
Variable
Experimental Group 
(n = 18)
Control Group 
(n = 31) P
Mean (SD) n (%) Mean (SD) n (%)
Age (years) 8.8(2.1) 8.4(3.0) 0.92*
Sex 0.56**
Female 10(55.6) 20(64.5)
Male 8(44.4) 11(35.5)
Reproductive status 0.76**
Intact 7(38.9) 10(32.3)
Neutered 11(61.1) 21(67.7)
Tumor recurrence prior vinblastine chemotherapy 0.14**
Yes 6(33.3) 4(12.9)
No 12(66.7) 27(87.1)
Onset time (months) 3.8(3.9) 5.6(8.6) 0.50*
 Number of lesions 0.53**
1 10(55.6) 20(64.5)
≥2 8(44.4) 11(35.5)
Tumor location 0.61**
Head/neck 2(11.1) 8(25.8)
Trunk 8 (44.4) 12(38.7)
Extremity 6(33.3) 7(22.6)
Inguinal/perineal 2(11.1) 4(12.9)
Skin ulceration 0.18**
Present 8(44.4) 8(25.8)
Absent 10(55.6) 23(74.2)
Sign of abdominal metastasis 0.07***
Present 0(0.0) 6(19.4)
Absent 18(100.0) 25(80.6)
Histological grade† 0.66***
II 15(83.3) 28(90.3)
III 3(16.7) 3(9.7)
Histological grade‡ 0.55**
Low-grade 12(66.7) 18(58.1)
High-grade 6(33.3) 13(41.9)
†Reference 13; ‡Reference 7; *Mann-Whitney test, P < 0.05; **Chi-square test, P < 0.05; ***Fisher’s exact test, P < 0.05.
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Table 2. Distribution of hematological parameters of 18 dogs treated with 3 mg/m2 vinblastine (EG) before the start of chemotherapy treatment (T0) and 
during the subsequent four sessions (T1 to T4).
Parameter
Start
(T0)
1st week 
(T1)
2nd week
(T2)
3rd week
(T3)
4th week
(T4)
P T0 x Tn P
Mean
(SD)†
Mean
(SD)†
Mean
(SD)†
Mean
(SD)†
Mean
(SD)†
Erythrocytes (106/µL) 6.8(1.0)
6.4
(1.2)
6.0
(1.2)
6.0
(1.2)
5.5
(1.3) <0.001* T0 > T1 0.78**
T0 > T2  0.04**
T0 > T3 0.07**
T0 > T4 0.001**
Hemoglobin (g/dL) 16.0(2.2)
15.2
(2.4)
14.1
(2.6)
14.3
(2.8)
13.4
(3.2) <0.001* T0 > T1 0.89**
T0 > T2 0.03**
T0 > T3 0.06**
T0 > T4 0.001**
Hematocrit (%) 46.7(5.6)
44.2
(7.0)
41.4
(6.7)
40.8
(6.7)
38.8
(8.5) < 0.001* T0 > T1 0.04**
T0 > T2 0.01**
T0 > T3 < 0.01**
T0 > T4  0.001**
Platelets (103/µL) 302.7(118.1)
330.7
(136.2)
304.9
(98.0)
313.7
(97.6)
300.7
(75.2) 0.81* - -
Leukocytes (103/µL) 12.3(9.0)
12.2
(6.0)
12.9
(14.9)
15.7
(19.0)
16.4
(18.9) 0.05*** - -
Eosinophils (/µL) 438.9(359.6)
504.4
(441.0)
43.1
(55.2)
157.9
(218.9)
183.3
(259.3) <0.001*** T0 > T1 0.40**
T0 > T2  0.001****
T0 > T3 0.02****
T0> T4 0.01****
Basophils (/µL) 6.3(26.9)
53.5
(159.9)
5.4
(22.9)
0.0
(0.0)
0.0
(0.0) 0.34*** - -
Lymphocytes (/µL) 1700.2(1047.9)
1483.6
(927.9)
1539.1
(1119.7)
1962.4
(1397.2)
1608.9
(991.8) 0.31*** - -
Monocytes (/µL) 699.5(792.4)
646.3
(467.3)
1115.4
(1176.0)
1222.5
(1299.6)
2006.0
(4307.6) 0.03*** T0 < T1 0.79****
T0 < T2 0.02****
T0 < T3 0.01****
T0 < T4 0.36****
Neutrophils (/µL) 10005.0(7995.2)
9575.4
(5890.2)
10203.4
(13274.7)
12325.6
(18017.4)
12629.5
(16391.3) 0.08*** - -
*Repeated measures ANOVA with Bonferroni correction; **Dependent t-test; ***Friedman test; ****Wilcoxon test; †SD= standard deviation.
In both groups, there was higher-grade neutro-
penia one week after the first VBL application (T2). 
There was no significant difference in neutrophil counts 
between the groups at T2 (P = 0.40; Table 4). At T2, 
the EG group showed five dogs (27.8%) with some 
grade of neutropenia: one dog (5.6%) with neutropenia 
grade 1, 2 and 4, and two dogs with neutropenia grade 
3 (11.1%). The number of neutropenic dogs from EG 
was also five at T3, with different distribution in grades: 
four dogs with neutropenia grade 1, and one dog with 
neutropenia grade 2. In comparison, the CG showed 
reduction from five neutropenic dogs in T2 (three grade 
1, one grade 2, and one grade 3 neutropenia) to four in 
T3 (all cases classified as grade 1 neutropenia). Prior to 
the fourth session (T4), one (5.6%) EG dog presented 
grade 1 neutropenia and two (6.4%) CG dogs had 
grade 2 neutropenia. Platelet values remained stable 
in most dogs in both the groups. At T1, only one EG 
dog (5.6%) and two CG dogs (3.2%) presented grade 
1 thrombocytopenia.
In the EG, eight dogs (44.4%) presented gastro-
intestinal adverse effects classified as grade 1 anorexia 
(n= 1; 5.5%), grade 1 vomiting (n= 4; 22.0%), grade 1 
diarrhea (n= 1; 5.5 %), and one dog (5.5%) presented 
grade 2 diarrhea after the first session. In the CG, nine 
dogs (29.0%) presented gastrointestinal toxicity classi-
6                                                                                                           L.C. Kluthcovsky, B.F. Firmo, P.C. Cassino, et al. 2020. Comparison of Two Different Vinblastine Dosages for Treatment of Cutaneous 
Mast Cell Tumor in Dogs.                                                                                                                  Acta Scientiae Veterinariae. 48: 1739.
Table 3. Distribution of hematological parameters of 31 dogs treated with 2 mg/m2 vinblastine (CG) before the start of chemotherapy treatment (T0) 
and during the subsequent four sessions (T1 to T4). 
Parameter
Start
(T0)
1st week 
(T1)
2nd week
(T2)
3rd week
(T3)
4th week
(T4) P T0 x Tn PMean
(SD)†
Mean
(SD)†
Mean
(SD)†
Mean
(SD)†
Mean
(SD)†
Erythrocytes (106/ µL) 6.4(1.2)
6.4
(1.3)
6.2
(1.0)
6.3
(0.9)
6.1
(0.8) 0.24* - -
Hemoglobin (g/dL) 15.6(3.1)
15.7
(3.0)
15.0
(2.6)
14.9
(2.2)
14.9
(2.1) 0.02* T0 < T1 1.00***
T0 > T2 0.46***
T0 > T3 0.60***
T0 > T4 1.00***
Hematocrit (%) 43.8(9.0)
44.1
(9.2)
42.1
(7.4)
42.7
(6.8)
41.6
(5.4) 0.06* - -
Platelets (103/ µL) 390.2(246.7)
407.7
(166.6)
448.3
(226.5)
404.4
(187.7)
508.3
(527.5) 0.56** - -
Leukocytes (103/ µL) 10.4(4.4)
9.1
(3.7)
6.8
(2.9)
8.4
(4.6)
8.5
(4.3) 0.001** T0 > T1 0.18****
T0 > T2 < 0.001****
T0 > T3 0.01****
T0 > T4 0.06****
Eosinophils (/µL) 584.3(676.4)
435.9
(531.0)
84,7
(255.1)
110.4
(123.1)
178.5
(265.2) <0.001** T0 > T1 0.18****
T0 > T2 < 0.001****
T0 > T3 < 0.001****
T0 > T4 < 0.001****
Basophils (/µL) 0.0(0.0)
14.2
(67.1)
15.9
(63.4)
16.5
(92.0)
6.8
(27.2) 0.52** - -
Lymphocytes (/µL) 1390.5(672.8)
1599.7
(2066.3)
1542.4
(2277.2)
1066.7
(746.6)
1359.2
(1157.2) 0.02** T0 > T1 0.30****
T0 > T2 0.02****
T0 > T3 0.01****
T0 > T4 0.27****
Monocytes (/µL) 292.0(224.4)
252.7
(225.9)
332.8
(380.1)
337.0
(324.4)
299.9
(248.7) 0.97** - -
Neutrophils (/µL) 8021.6(4229.7)
7159.2
(3604.4)
5403.6
(2712.0)
7031.7
(4290.0)
6873.4
(4225.2) 0.15** - -
*Repeated measures ANOVA with Bonferroni correction; **Friedman test; ***Dependent t-test; ****Wilcoxon test; †SD= standard deviation.
Table 4. Distribution of experimental and control dogs, seven days after the first vinblastine application (T2), according to grades of neutropenia.
Grade of neutropenia
Treatment Protocol (T2)
Experimental Group (n = 18)*
n (%)
Control Group (n = 31)*
n (%)
No neutropenia 13(72.2) 26(83.9)
1 (1500/µL-LLN) 1(5.6) 3(9.7)
2 (1000-1499/µL) 1(5.6) 1(3.2)
3 (500-999/µL) 2(11.1) 1(3.2)
4 (<500/µL) 1(5.6) 0(0.0)
*Non-significant difference following the Pearson Chi-square test (P = 0.40); LLN= lower limit of normal (3000 neutrophils/µL)
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fied as grade 1 anorexia (n= 2; 6.5%), grade 1 vomit-
ing (n= 2; 6.5%), grade 1 diarrhea (n= 3; 9.7%), and 
grade 2 diarrhea (n= 2; 6.5%). These adverse effects 
were mild and self-limited in both groups and there 
was no interruption in treatment in any groups due to 
gastrointestinal toxicity.
After chemotherapy, tumor recurrence was 
observed in four of the 18 dogs in the EG (22.2%) and 
in 13 of the 25 dogs in the CG (52.0%), with significant 
difference (P = 0.02) between groups. 
Figure 1 shows the overall survival curves for 
the two groups. There was no significant difference in 
the overall survival between the groups (P = 0.11). A 
cross-sectional analysis of the overall survival of the 
dogs showed that over the period of 365 days (one 
year) after the histopathological diagnosis, the overall 
survival for the EG was 66.2% and that for the CG was 
80.9%; there was no significant difference between the 
groups (P = 0.05).
DISCUSSION
This study evaluated the treatment of MCT in 
dogs in two groups: one group treated with a higher 
VBL dose (3 mg/m²) and the other group treated with 
the classic dose (2 mg/m²). There were no significant 
differences following comparison of the clinical vari-
ables between groups. These finding suggests that the 
groups may be similar regarding these variables. Initial 
exclusion of dogs with grade I MCT in both groups 
was based on previously published recommendations 
for chemotherapy treatment, once dogs with grade I/
low-grade MCT usually have a more favorable out-
come when compared to those high-grade or grades 
Figure 1. Kaplan-Meier survival curve for dogs of Experimental Group 
and Control Group follow-up after diagnosis.
II/III MCT [2,17,19]. The mean ages for middle-aged 
dogs and elderly dogs for both groups were similar. 
These ages correspond to the age of MCT occurrence 
in dogs [10,15,16]. The frequency of high-grade tumors 
increases significantly mainly in elderly dogs with re-
lapse. This possibly occurs due to the increased number 
of additional mutations over time [10].
The hematological parameters of the EG and 
CG were analyzed separately just before the start of 
treatment until the fourth session with VBL and pred-
nisone. Currently, the use of VBL and prednisone in 
chemotherapy is recommended for the management 
of dogs with MCT, especially in cases involving high-
grade tumors, unresectable tumors, and compromised 
surgical margins after excision [17]. VBL is a vinca 
alkaloid that acts during the mitosis stage of the cell 
cycle. It binds to protein microtubules in the mitotic 
spindle, eventually preventing cell replication and re-
ducing mitosis. This action is non-selective, and may 
cause cytotoxicity in healthy and neoplastic cells [25]. 
Therefore, dogs undergoing VBL treatment should be 
evaluated regularly using the CBC to identify possible 
cytopenias, mainly anemia, neutropenia, and thrombo-
cytopenia. Other adverse effects that may be observed 
during treatment are gastrointestinal adverse effects, 
which include anorexia, vomiting, and diarrhea [1,12].
The occurrence of anemia is a constant concern 
in patients undergoing chemotherapy treatment in vet-
erinary oncology [8]. In this study, dogs in both groups 
exhibited reduction in at least one parameter associ-
ated with the erythrogram. However, the hemoglobin, 
erythrocyte, and hematocrit values did not exceed the 
lower reference limits for the species. There was no 
identification of severe anemia during the treatment 
in both groups. Significant reduction in hematocrit 
or other erythrogram parameters was not previously 
described as a common adverse effect during VBL 
treatment [1,15,20]. In the CG, there was a significant 
reduction in the hemoglobin values over the four ses-
sions. However, these values were not significantly 
correlated with the initial value observed at T0. 
It is important to emphasize that groups were 
compared using multivariate analysis of variance using 
variables that were significant following the bivariate 
analysis (hemoglobin and eosinophils) between T0 and 
T4. There was significant reduction in hemoglobin and 
eosinophil in both groups during the treatment period. 
However, there was no significant difference in the 
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values of these hematological parameters between 
the EG and CG when the VBL dose was used as the 
dependent variable. These results may suggest that both 
the usual dose and the highest dose of VBL result in 
similar hematological toxicity between groups.
The cytotoxic effect of VBL is more evident 
in cells with a high replication rate, such as neutro-
phils [20]. In the present study, the highest number 
of neutropenia episodes occurred during T2, after 
the first VBL application in both groups. The neu-
trophil values tended to stabilize after T2 and there 
was less occurrence of neutropenia after the second 
chemotherapy session. This finding was observed in 
previous studies, which also showed a trend towards 
stabilization of neutrophil values after treatment 
started [3,20]. Temporary interruption of treatment 
is recommended whenever CBC shows significant 
neutropenia, this will allow normalization of neu-
trophil values and avoid possible side effects due to 
immunosuppression [2,20,22].
In a previous study, administration of VBL 
at a dose of 3.5 mg/m² caused grade 4 neutropenia 
in 46% of 26 treated dogs. The main outcome of the 
study was the evaluation of tumor size using VBL as a 
single agent for treatment. The response rate observed 
in the group of dogs receiving a dose of 2 mg/m² was 
11.8%, while the 3.5 mg/m² group had a response rate 
of 27% [14]. In the present study, although some dogs 
had macroscopic disease during treatment, the response 
rate relative to the reduction in tumor size was not the 
primary outcome. 
Although adverse effects are generally mild 
during VBL chemotherapy, there is a description of a 
dog that exhibited grade 4 neutropenia, subsequently 
resulting in death due to sepsis during VBL treat-
ment [3]. In the present study, no dog in the EG and 
CG died during treatment. Also, we detected grade 
4 neutropenia only in one dog in the EG after the 
first VBL administration. This case showed improve-
ment in the neutrophil count after one interval week. 
The number of neutropenia episodes was not sig-
nificantly different between groups, which suggests 
that 3 mg/m² of VBL is safe regarding neutrophil 
count. A study with staggered VBL doses in dogs 
confirmed the safety of administering a dose of 3.5 
mg/m². However, there was a higher frequency of 
neutropenia [1]. Another study evaluated the use 
of rapidly increasing VBL doses over a period of 
two weeks. In the aforementioned study, 70% of 
34 dogs tolerated the 3 mg/m² well. Additionally, 
neutropenia was the most observed adverse effect 
and factors such as response rate and survival time 
were not evaluated [21].
In addition to a follow-up CBC test, the 
evaluation of gastrointestinal effects is important as 
a parameter to measure toxicity during chemotherapy 
MCT treatment. In the present study, gastrointestinal 
adverse events were mild and self-limited in both 
groups. Similar findings were also described in previ-
ous studies [4,15,21,23].
Tumor recurrence is often an important factor 
when evaluating the efficacy of treatments for MCT 
in dogs [9,12]. The exact role of the VBL dose in the 
relapse and survival of dogs with MCT is still in debate. 
A study involving 35 dogs with high-grade, metastatic, 
or disseminated MCTs evaluated a combined therapy 
with 3.5 mg/m² dose of VBL and prednisone. The 
response rate was 65% and there was recurrence in 
16 dogs, with a mean disease free time of 489 days. 
Survival time was significantly lower for dogs with 
grade III MCT, indicating that the histopathological 
grade is an important factor associated with survival 
[15]. Regarding relapse after treatment in the present 
study, EG dogs had significantly less tumor recurrence 
than the dogs in the CG. This finding suggests that 
using larger VBL doses for the treatment of MCT in 
dogs might be beneficial.
The relationship between dose intensity and 
efficacy in veterinary oncology remains unclear for 
several types of tumors. A study involving dogs with 
lymphoma showed that higher doses of chemotherapy 
might promote positive therapeutic and prognostic 
response, although they can cause more adverse 
effects than the doses used in traditional protocols. 
The increase in dosage, however, should be gradual 
and often personalized [18]. One preliminary study 
evaluated the use of VBL for treatment of naïve mul-
ticentric lymphoma in dogs. In that study, dogs were 
treated with 2 mg/m² doses of VBL while a small 
subset of dogs were treated with 2.5 mg/m² doses 
of VBL. Dogs treated with a higher VBL dose had 
significantly improved response rates, suggesting that 
an increase in the VBL dose may improve efficacy in 
some cases [4].
A long follow-up period is required to es-
tablish the actual beneficial effect of a higher dose 
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of VBL for the treatment of MCT [5]. Although 
previous studies evaluated higher doses of VBL for 
MCT treatment in dogs, their focus was on evaluat-
ing the toxicity and identifying safe dosages and 
the long-term effect of a higher dose was not an 
endpoint [14,21,23]. In the present study, the overall 
survival following diagnosis revealed no significant 
difference between EG and CG. A cross-sectional 
analysis of the overall survival of the dogs showed 
that over the period of 365 days (one year) after 
the histopathological diagnosis, there was also no 
significant difference between groups. These results 
suggest that higher doses of VBL do not negatively 
affect survival.
The importance of MCT in dogs in the field of 
veterinary oncology is evident in this and other studies. 
The variable clinical presentation consists of factors 
that make it difficult to choose an optimal treatment 
protocol. This study had limitations, which include 
a limited follow-up period, small sample size and 
absence of surgical margins evaluation data. Despite 
these limitations, we presented an epidemiological 
profile of dogs with grade II and III MCT at two dif-
ferent treatment centers. 
CONCLUSIONS
The study evaluated the treatment of MCT over 
a period in dogs using a higher dose of VBL compared 
with controls, which received the standard dose of VBL. 
The comparison between groups revealed similar adverse 
effects. The reductions in hematological parameters did not 
exceed the lower limit for the species. The experimental 
group had a lower rate of tumor recurrence than the control 
group. The results suggest that higher doses of vinblastine 
may be possible for dogs with cutaneous MCT.
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